Otros idiomas Jazz Pharmaceuticals plc Sao Paulo

Acciones

J2AZ34

BRJ2AZBDR009

Mercado cerrado - Sao Paulo Otros sitios de cotización 15:17:51 10/05/2024			Varia. Cinco días.	Varia. 1 de enero.
38,72 ^BRL	-0,56 %		-.--%	-10,95 %

20/06	JAZZ PHARMACEUTICALS PLC : Needham & Co. mantiene su recomendación de compra	ZM
20/06	Actualización del sector: Las acciones de atención médica bajaron antes de la campana del jueves	MT

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Sector Update: Health Care Stocks Lean Lower Pre-Bell Thursday	20/06
Sector Update: Health Care	20/06
Jazz Pharmaceuticals Says Phase 2b Trial for Suvecaltamide Misses Primary Endpoint -- Shares Slump Pre-Bell	20/06
Jazz Pharmaceuticals' tremor drug fails to meet main goal in mid-stage study	20/06
Jazz Pharmaceuticals Provides Update on Phase 2b Trial of Investigational Suvecaltamide (JZP385) in Essential Tremor	20/06
Jazz Pharmaceuticals plc Provides Update on Phase 2b Trial of Investigational Suvecaltamide in Essential Tremor	20/06
Jazz Pharmaceuticals : 2023 Annual Report	15/06
Surging Biotech M&A Reaffirms Massive Opportunity In Rare Disease Drug Development (CRDL,JAZZ, NVO, AZN, SNY)	11/06
Jazz Pharmaceuticals Presents Overall Survival and Longer Follow-Up Data from HERIZON-BTC-01 Trial Evaluating Zanidatamab in Previously Treated HER2-Positive Biliary Tract Cancer at ASCO 2024	01/06
Jazz Pharmaceuticals plc Announces Catherine Sohn, Pharm.D. Will Not Stand for Re-Election to the Board	31/05
Jazz Pharmaceuticals plc - Zanidatamab Granted Priority Review for HER2-Positive Metastatic Biliary Tract Cancer	30/05
Jazz Pharmaceuticals Showcases Pioneering Research in Sleep Medicine at SLEEP 2024	30/05
Jazz Pharmaceuticals Showcases Pioneering Research in Sleep Medicine at SLEEP 2024	30/05
Jazz Pharmaceuticals to Participate in Upcoming June Investor Conferences	29/05
Sector Update: Health Care Stocks Lean Lower Premarket Wednesday	29/05
Jazz Pharmaceuticals Says US FDA Grants Zanidatamab Priority Review to Treat HER2-Positive Metastatic Biliary Tract Cancer	29/05
Jazz Pharmaceuticals plc Announces the U.S. Food and Drug Administration Accepted and Granted Priority Review of the Biologics License Application for Zanidatamab	29/05
Jazz Pharmaceuticals Announces Collaboration with Life Science Cares to Improve the Wellbeing of Under Resourced Communities through Employee Volunteerism	22/05
US reclassification could drive fresh research funding into pot sector	13/05
Jazz Pharmaceuticals Insider Sold Shares Worth $548,250, According to a Recent SEC Filing	07/05

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Jazz Pharmaceuticals plc Sao Paulo

Acciones

J2AZ34

BRJ2AZBDR009

Otros idiomas

Filtros